Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: A review of the literature

Bester, Lourens; Meteling, Baerbel; Boshell, David; Chua, Terence C.; Morris, David L.

doi:10.1111/1754-9485.12163

Cited by 50 publications

(28 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8 Most commonly, the mixture of chemotherapeutics and Lipiodol is injected first, followed by the injection of embolizing particles until stagnation or reflux in the hepatic artery is documented. 13 Mitomycin, cisplatin and doxorubicin are frequently used chemotherapeutic drugs for intra-arterial infusion (Table 1). 5 TACE usually causes no serious adverse effects.…”

Section: Current Trends In Interventional Treatment Of Colorectal Canmentioning

confidence: 99%

Current strategies in interventional oncology of colorectal liver metastases

Gruber‐Rouh

Marko

Thalhammer

et al. 2016

BJR

View full text Add to dashboard Cite

The adequate treatment of non-resectable liver metastases from colorectal cancer which are resistant to systemic chemotherapy currently provides a great challenge. The aim is to identify and review key strategies in the treatment of colorectal liver metastases. A search for current literature on the topic of interventional strategies for colorectal metastases was performed in Medline in order to achieve this goal. Studies before 2005 and with ,20 patients treated for colorectal metastases were excluded. Transarterial chemoembolization (TACE), transarterial embolization and selective internal radiation therapy (SIRT) were identified as examples of regional strategies for colorectal liver metastases, utilizing the unique blood supply of the liver. Radiofrequency ablation (RFA), microwave ablation (MWA) and cryoablation were selected as examples for currently available ablative techniques. Median survival in the key studies reviewed ranged from 7.7 to 28.6 for TACE, 8.3-12.6 for SIRT, 8.2-53.2 for RFA and 29-43 months for MWA. After review of the literature, it can be concluded that interventional oncologic therapies are a safe and effective method for treating colorectal liver metastases. The use of new chemotherapeutic agents for local therapy and new ablation technologies and techniques may increase patient survival and allows a neoadjuvant therapy setting. In addition, a combination of local therapies may be used to increase effectiveness in the future, which is subject to further research. INTRODUCTIONColorectal cancer is one of the most common cancers that shows fatal progression.1 Colorectal carcinoma most commonly metastasises to the liver due to haematogenous spread.2 At the time of diagnosis, 20-30% of patients have liver metastases, and during the course of disease, up to 60% of patients develop hepatic metastases.3 Although surgical excision is the first-line treatment for colorectal metastases, only 10-25% of patients are candidates for surgical resection. 4 Neoadjuvant systemic chemotherapy only allows 10-30% of patients with unresectable colorectal liver metastases sufficient downsizing for resection.

show abstract

Section: Current Trends In Interventional Treatment Of Colorectal Canmentioning

confidence: 99%

Current strategies in interventional oncology of colorectal liver metastases

Gruber‐Rouh

Marko

Thalhammer

et al. 2016

BJR

View full text Add to dashboard Cite

show abstract

“…While transarterial embolization involves selective instillation of embolic materials (eg, Gelfoam [Pharmacia & Upjohn], polyvinyl alcohol) into the hepatic arteries, TACE refers to administration of chemotherapeutic agents (doxorubicin, cisplatin, or mitomycin C) with or without ethiodized oil in combination with embolic particles to increase the efficacy of tumor destruction (13,14). SIRT, or radioembolization, is a form of brachytherapy that involves intra-arterial administration of micron-sized particles (20-60 μm) containing yttrium 90 ( 90 Y), which deliver focused β radiation to cause tumor destruction while minimizing radiation damage to the surrounding normal liver (13)(14)(15). Unlike TACE, SIRT requires preservation of adequate perfusion to the tumor to enhance free radical-dependent cell death from radiation therapy (13)(14)(15).…”

Section: Intra-arterial Therapiesmentioning

confidence: 99%

Image-guided Treatment in the Hepatobiliary System: Role of Imaging in Treatment Planning and Posttreatment Evaluation

Bajpai¹,

Kambadakone²,

Guimarães³

et al. 2015

RadioGraphics

View full text Add to dashboard Cite

In the past decade, image-guided targeted treatments such as percutaneous ablation, intra-arterial embolic therapies, and targeted radiation therapy have shown substantial promise in management of hepatobiliary malignancies. Imaging is integral to patient selection, treatment delivery, and assessment of treatment effectiveness. Preprocedural imaging is crucial and allows local tumor staging, evaluation of surrounding structures, and selection of suitable therapeutic options and strategies for treatment delivery. Postprocedural imaging is required to monitor therapeutic success, detect residual or recurrent disease, and identify procedure-related complications to guide appropriate future therapy. Technical innovations in cross-sectional imaging techniques such as computed tomography (CT) and magnetic resonance (MR) imaging, combined with advances in image postprocessing and new types of contrast agents, allow precise morphologic assessment and functional evaluation of hepatobiliary tumors. Advanced postprocessing techniques such as image fusion and volumetric assessment not only facilitate procedural planning and treatment delivery but also enhance posttreatment imaging surveillance. In addition, molecular imaging techniques such as fluorodeoxyglucose positron emission tomography (PET), PET/CT, and PET/MR imaging offer opportunities to evaluate various physiologic properties of tumors.

show abstract

“…Preoperative TACE has been used to control primary liver neoplasm (21). However, the outcome for certain patients is unsatisfactory due to the malignant nature of the tumor.…”

Section: B Cmentioning

confidence: 99%

Synchronous double primary cancer - intrahepatic cholangiocarcinoma with bone metastases and thyroid carcinoma: A case report

Wang

Zhao

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. There is a low incidence of multiple primary cancer, particularly when the cancer is synchronous. The present report presents a case of synchronous double primary malignancies. A 58-year-old woman was admitted to Ling Nan Hospital (Guangzhou, China) complaining of pain in the left hip. X-ray revealed an osteolytic lesion and further examination indicated the presence of double primary cancer, consisting of hepatic cholangiocarcinoma and thyroid carcinoma. Biopsy of the osteolytic lesion showed a metastatic adenocarcinoma of unknown origin. Subsequently, final diagnosis was confirmed by I-131 scan and liver lesion biopsy. The patient received positive multidisciplinary treatments and survived for 9 months following diagnosis. The results of the present case suggest that multiplicity of primary malignancy is not necessarily an indicator of poor prognosis, as long as effective diagnosis and adequate disease management are achieved.

show abstract

Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: A review of the literature

Cited by 50 publications

References 71 publications

Current strategies in interventional oncology of colorectal liver metastases

Current strategies in interventional oncology of colorectal liver metastases

Image-guided Treatment in the Hepatobiliary System: Role of Imaging in Treatment Planning and Posttreatment Evaluation

Synchronous double primary cancer - intrahepatic cholangiocarcinoma with bone metastases and thyroid carcinoma: A case report

Contact Info

Product

Resources

About